News

In The News ADVI’s Lindsay Bealor Greenleaf sat down with the Daily Caller to discuss some of the problems that this proposal would have posed for patients
In The News “Insulins are typically heavily rebated products, and Part D beneficiaries’ out-of-pocket costs are based on a pre-rebated list price,” ADVI VP Lindsay Bealor Greenleaf explained to BioWorld about the costs of insulin
In The News Following the White House’s announcement on insulin cost caps in Medicare, ADVI’s Lindsay Bealor Greenleaf sat down with the American Journal of Managed Care to share her thoughts
In The News ADVI’s Dr. Michael Kolodziej and Texas Oncology’s Dr. Debra Patt share their thoughts on how COVID-19 is impacting the oncology space through the lens’ of patients, providers, payers, and other areas in The Cancer Letter
In The News ADVI’s Lindsay Bealor Greenleaf spoke with the American Journal of Managed Care to Discuss the State of Medicare Advantage and Impacts from the Covid-19 Outbreak
In The News ADVI’s Dr. Michael Kolodziej caught up with the Cancer Support Community podcast to discuss the coronavirus and finding support in the community during social distancing
In The News ADVI’s Kip Piper shared his thoughts on the financing mechanisms around the ACA for Modern Healthcare’s special coverage of the law’s 10-year anniversary
In The News ADVI’s Marc Samuels talks with Modern Healthcare about drug pricing in the State of the Union
In The News ADVI CEO Marc Samuels caught up with Modern Healthcare to discuss the likelihood of Congress enacting drug pricing reforms during an election year